百时美施贵宝Bristol Myers Squibb Co. (BMY) 2023年年度报告「NYSE」.pdf

1、2023 Annual ReportOur MissionTo discover,develop and deliver innovative medicines that help patients prevail over serious diseasesOur VisionTo be the worlds leading biopharma company that transforms patients lives through scienceOur ValuesIntegrity Innovation Urgency Passion Accountability Inclusion

2、 Atiba Page is always a naturally happy person.When she was diagnosed with cancer,she was devastated and knew that a positive attitude was one of her biggest strengths.While joining Bristol Myers Squibb during her treatment journey,she found strength and support in her colleagues.Scan the QR code to

3、 learn more about Atibas journey.2024 Bristol-Myers Squibb Company.All rights reserved.ON THE COVER:A decade ago,the first Coast 2 Coast 4 Cancer cycling event began with 53 employees riding 3,000 miles across the U.S.to honor loved ones impacted by cancer by raising funds for cancer research.Now,th

4、ere are more than 350 participants from 23 countries,covering more than 6,000 miles for cancer.Scan the QR code to learn more about Coast 2 Coast 4 Cancer.Building a Foundation for Sustainable Growth$45.0B$3.86$7.513%77%Bristol Myers Squibb 2023 Annual ReportGAAP EPS1TOTAL NET SALESIn-Line Brand YoY

5、%revenue growthNew Product Portfolio YoY%growth*NON-GAAP EPS1,2 A decrease of 2%both as reported and when adjusted for foreign exchange.Or 4%when adjusted for foreign exchange.*Or 76%when adjusted for foreign exchange.1 GAAP and non-GAAP EPS include the net impact of Acquired IPRD charges and licens

6、ing income of($0.28)per share for the full year 2023.Acquired IPRD refers to certain in-process research and development(Acquired IPRD)charges resulting from upfront or contingent milestone payments in connection with asset acquisitions or licensing of third-party intellectual property rights.2 Non-